A Miccheli1, G Capuani1, F Marini1, A Tomassini1, G Praticò1, S Ceccarelli2, D Gnani2, G Baviera3, A Alisi4, L Putignani5, V Nobili4. 1. Department of Chemistry, Sapienza University of Rome, Rome, Italy. 2. Liver Research Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy. 3. Family Pediatrician, Rome, Italy. 4. 1] Liver Research Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy [2] Hepato-Metabolic Disease Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy. 5. 1] Parasitology Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy [2] Metagenomics Unit, 'Bambino Gesù' Children's Hospital, IRCCS, Rome, Italy.
Abstract
BACKGROUND: Nowadays, non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in children. Our recent clinical trial demonstrated that dietary and VSL#3-based interventions may improve fatty liver by ultrasound and body mass index (BMI) after 4 months. OBJECTIVES: As in this short-term trial, as in others, it is impracticable to monitor response to therapy or treatment by liver biopsy, we aimed to identify a panel of potential non-invasive metabolic biomarkers by a urinary metabolic profiling. METHODS:Urine samples from a group of 31 pediatric NAFLD patients, enrolled in a VSL#3 clinical trial, were analyzed by high-resolution proton nuclear magnetic resonance spectroscopy in combination with analysis of variance-Simultaneous Component Analysis model and multivariate data analyses. Urinary metabolic profiles were interpreted in terms of clinical patient feature, treatment and chronology pattern correlations. RESULTS:VSL#3 treatment induced changes in NAFLD urinary metabolic phenotype mainly at level of host amino-acid metabolism (that is, valine, tyrosine, 3-amino-isobutyrate or β-aminoisobutyric acid (BAIBA)), nucleic acid degradation (pseudouridine), creatinine metabolism (methylguanidine) and secondarily at the level of gut microbial amino-acid metabolism (that is, 2-hydroxyisobutyrate from valine degradation). Furthermore, some of these metabolites correlated with clinical primary and secondary trial end points after VSL#3 treatment: tyrosine and the organic acid U4 positively with alanine aminotransferase (R=0.399, P=0.026) and BMI (R=0.36, P=0.045); BAIBA and tyrosine negatively with active glucagon-like-peptide 1 (R=-0.51, P=0.003; R=-0.41, P=0.021, respectively). CONCLUSIONS:VSL#3 treatment-dependent urinary metabotypes of NAFLD children may be considered as non-invasive effective biomarkers to evaluate the response to treatment.
RCT Entities:
BACKGROUND: Nowadays, non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver diseases in children. Our recent clinical trial demonstrated that dietary and VSL#3-based interventions may improve fatty liver by ultrasound and body mass index (BMI) after 4 months. OBJECTIVES: As in this short-term trial, as in others, it is impracticable to monitor response to therapy or treatment by liver biopsy, we aimed to identify a panel of potential non-invasive metabolic biomarkers by a urinary metabolic profiling. METHODS: Urine samples from a group of 31 pediatric NAFLD patients, enrolled in a VSL#3 clinical trial, were analyzed by high-resolution proton nuclear magnetic resonance spectroscopy in combination with analysis of variance-Simultaneous Component Analysis model and multivariate data analyses. Urinary metabolic profiles were interpreted in terms of clinical patient feature, treatment and chronology pattern correlations. RESULTS: VSL#3 treatment induced changes in NAFLD urinary metabolic phenotype mainly at level of host amino-acid metabolism (that is, valine, tyrosine, 3-amino-isobutyrate or β-aminoisobutyric acid (BAIBA)), nucleic acid degradation (pseudouridine), creatinine metabolism (methylguanidine) and secondarily at the level of gut microbial amino-acid metabolism (that is, 2-hydroxyisobutyrate from valine degradation). Furthermore, some of these metabolites correlated with clinical primary and secondary trial end points after VSL#3 treatment: tyrosine and the organic acid U4 positively with alanine aminotransferase (R=0.399, P=0.026) and BMI (R=0.36, P=0.045); BAIBA and tyrosine negatively with active glucagon-like-peptide 1 (R=-0.51, P=0.003; R=-0.41, P=0.021, respectively). CONCLUSIONS: VSL#3 treatment-dependent urinary metabotypes of NAFLD children may be considered as non-invasive effective biomarkers to evaluate the response to treatment.
Authors: Age K Smilde; Jeroen J Jansen; Huub C J Hoefsloot; Robert-Jan A N Lamers; Jan van der Greef; Marieke E Timmerman Journal: Bioinformatics Date: 2005-05-12 Impact factor: 6.937
Authors: Luca Miele; Giuseppe Marrone; Cristiano Lauritano; Consuelo Cefalo; Antonio Gasbarrini; Chris Day; Antonio Grieco Journal: Curr Pharm Des Date: 2013 Impact factor: 3.116
Authors: Alexander Wree; Lori Broderick; Ali Canbay; Hal M Hoffman; Ariel E Feldstein Journal: Nat Rev Gastroenterol Hepatol Date: 2013-08-20 Impact factor: 46.802
Authors: Yao Tang; Juan Huang; Wen Yue Zhang; Si Qin; Yi Xuan Yang; Hong Ren; Qin-Bing Yang; Huaidong Hu Journal: Therap Adv Gastroenterol Date: 2019-09-25 Impact factor: 4.409